Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14776 - 14800 of 15132 in total
AVR-RD-04 is an investigational gene therapy for cystinosis. It consists of autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting in codon-optimized cDNA encoding for functional human cystinosin.
Investigational
Investigational
AMP-201 comprises an adeno-associated virus type 8 vector (AAV8) encoding the collagen Q gene (COLQ). It is under investigation for the treatment of collagen Q congenital myasthenia.
Investigational
BGT-DTDS is an investigational gene therapy comprising an adeno-associated viral vector type 2 (AAV2) encoding the human SLC6A3 gene. It is under investigation for the treatment of dopamine transporter deficiency syndrome (DTDS).
Investigational
RGG0853 is an E1A lipid complex, a repressor gene complexed with a cationic lipid vector.
Investigational
Ozekibart is a tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5). It is being investigated for the treatment of chondrosarcoma.
Investigational
MBP134 is a pan-ebolavirus cocktail comprising two broadly neutralizing human antibodies. It is under investigation for the treatment of Sudan ebolavirus (SUDV).
Investigational
EDIT-101 is a recombinant adeno-associated virus pseudotyped with serotype 5 viral capsid encoding CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9) gene editing constructs.
Investigational
The Cellspan Esophageal ImplantTM (CEI) composes of autologous adipose-derived mesenchymal stromal cells (Ad-MSC) seeded onto a polyurethane tubular mesh cell delivery device.
Investigational
ISA101b (peltopepimut-S) is a therapeutic vaccine against the HPV-specific E6/E7 oncoproteins.
Investigational
ABBV-706 is an antibody-drug conjugate that is anti-SEZ6.[L49156,L49161]
Investigational
CN-201 is a humanized anti-CD3/CD19 bispecific antibody.
Investigational
HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment of hepatocellular carcinoma.
Investigational
HTPEP-001 is a novel peptide that works to inhibit the activation of transforming growth factor beta (TGF-β). It is being investigated for the treatment of fibrosis.
Investigational
Sacituzumab tirumotecan is a recombinant humanized IgG1 anti-TROP2 monoclonal antibody conjugated to a topoisomerase I inhibitor.
Investigational
Sasanlimab is under investigation in clinical trial NCT06218069 (Immuno-pet Imaging Responses Administered Immune Checkpoint Inhibitor).
Investigational
Ragifilimab is under investigation in clinical trial NCT04225039 (Anti-gitr/anti-pd1/stereotactic Radiosurgery, in Recurrent Glioblastoma).
Investigational
Sigvotatug vedotin (SGN-B6A) is a humanized immunoglobulin G1 anti-integrin beta-6 monoclonal antibody conjugated to monomethyl auristatin E.
Investigational
RO7200220 is a recombinant fully humanized anti-IL 6 monoclonal antibody.
Investigational
Volrustomig is under investigation in clinical trial NCT06097728 (MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma).
Investigational
Lacripep is under investigation in clinical trial NCT03226444 (Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome).
Investigational
Acasunlimab is under investigation in clinical trial NCT06046274 (GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer).
Investigational
Petosemtamab is under investigation in clinical trial NCT03526835 (A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors).
Investigational
Vilamakitug is under investigation in clinical trial NCT05201352 (Evaluation of Efficacy of Trifluridine/tipiracil Plus an Anti-il-1α True Human Antibody Versus Trifluridine/tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine).
Investigational
Displaying drugs 14776 - 14800 of 15132 in total